Daily Stock Analysis, KIN, Kindred Biosciences Inc, priceseries

Kindred Biosciences Inc. Daily Stock Analysis
Stock Information
Open
8.25
Close
8.15
High
8.53
Low
8.05
Previous Close
8.24
Daily Price Gain
-0.09
YTD High
12.16
YTD High Date
Jan 8, 2019
YTD Low
5.96
YTD Low Date
Jul 23, 2019
YTD Price Change
-2.79
YTD Gain
-25.50%
52 Week High
12.32
52 Week High Date
Dec 14, 2018
52 Week Low
5.96
52 Week Low Date
Jul 23, 2019
52 Week Price Change
-3.74
52 Week Gain
-31.46%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 5. 2017
5.30
Jan 31. 2017
6.20
17 Trading Days
17.06%
Link
LONG
Jun 20. 2017
7.05
Jul 10. 2017
8.53
13 Trading Days
20.95%
Link
LONG
Sep 27. 2017
7.60
Oct 18. 2017
8.00
15 Trading Days
5.24%
Link
LONG
Dec 21. 2017
8.35
Jan 8. 2018
8.92
10 Trading Days
6.85%
Link
LONG
Apr 9. 2018
8.60
Apr 23. 2018
9.20
10 Trading Days
6.99%
Link
LONG
Jul 2. 2018
10.90
Aug 7. 2018
13.48
25 Trading Days
23.68%
Link
LONG
Oct 14. 2019
6.99
Nov 11. 2019
8.56
20 Trading Days
22.44%
Link
Company Information
Stock Symbol
KIN
Exchange
NasdaqCM
Company URL
http://www.kindredbio.com
Company Phone
650-701-7901
CEO
Richard H. Chin
Headquarters
California
Business Address
1555 BAYSHORE HIGHWAY, SUITE 200, BURLINGAME, CA 94010
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001561743
About

Kindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.

Description

Kindred Biosciences, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for pets. The company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. Its lead product candidates include Zimeta, a dipyrone injection for the control of pyrexia (fever) in horses; and Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats. The company's other small molecule product candidates consist of KIND-014 for the treatment of equine gastric ulcers in horses; and KIND-015 for the management of clinical signs associated with equine metabolic syndrome. It is also developing biologics programs, such as KIND-510, a feline recombinant erythropoietin for the control of non-regenerative anemia in cats; KIND-011, an anti-tumor necrosis factor (TNF) treatment for newborn foals; KIND-502 for the treatment of allergic and immune-mediated diseases; KIND-0888, an antibody that targets CD20; various antibodies that target cytokines involved in atopic dermatitis; KIND-509, an antibody that targets the canine TNF; and KIND-Bodies, a novel biologics with certain advantages over antibodies, including bispecific binding. The company was founded in 2012 and is headquartered in Burlingame, California.